Leaflet VALOMINDO 160mg / 1.5mg modified release tablets

Indicated for: hypertension

Route of administration: oral

Substance: valsartan + indapamide (angiotensin II receptor blocker + diuretic)

ATC: C09DA03 (Cardiovascular system | Angiotensin II receptor blockers (ARBs), combinations | Angiotensin ii receptor blockers (arbs) and diuretics)

Precautions:
Dose adjustment in renal impairment
Dose adjustment in renal impairment

Dose adjustment may be needed in kidney disease.

Contraindicated during pregnancy
Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hypotension / fall risk
Hypotension / fall risk

May lower blood pressure and increase the risk of falls.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Electrolyte disturbances
Electrolyte disturbances

This medicine may change blood electrolyte levels.

The combination of valsartan and indapamide is used for the treatment of hypertension, particularly in patients who do not respond adequately to monotherapy. Valsartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels and lowers blood pressure by blocking the effects of angiotensin II. Indapamide is a thiazide diuretic that helps eliminate excess salt and water from the body, thereby reducing blood pressure.

This combination is administered orally, usually once daily, and the dosage is adjusted based on the patient's response and blood pressure levels. It is important for patients to adhere to the treatment and regularly monitor their blood pressure.

Common side effects include dizziness, headaches, fatigue, and hypokalemia. In rare cases, severe adverse reactions such as renal failure, hyponatremia, or allergic reactions may occur.

The combination of valsartan and indapamide provides an effective option for managing hypertension, helping to reduce the risk of cardiovascular complications such as myocardial infarction or stroke.

General data about VALOMINDO 160mg / 1.5mg

  • Substance: valsartan + indapamide
  • Date of latest medicines list: 01-09-2024
  • Product code: W70467001
  • Concentration: 160mg / 1.5mg
  • Pharmaceutical form: modified release tablets
  • Quantity: 10
  • Product type: Generic medicine
  • Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

  • Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Holder: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Number: 15560/2024/01
  • Shelf life: 2 years

Concentrations available for valsartan + indapamide

  • 160mg/1.5mg
  • 80mg/1.5mg